Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood thinner trombix under Real-World review for heart rhythm disorder

NCT ID NCT06184204

Disease control Sponsor: Beker Laboratories Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study in Algeria followed 398 adults with atrial fibrillation who were taking the blood thinner Trombix (Rivaroxaban). The goal was to see how safe and effective the drug is in everyday medical practice, and how it affects quality of life. Researchers tracked serious bleeding events and other side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Rivaroxaban (brand name Trombix), a blood thinner
What this could lead to
If results are positive, this could confirm that Trombix is a safe and effective option for managing atrial fibrillation in real-world settings in Algeria.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to other populations or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

398 people

The number who actually took part.

Started

Dec 2023

Finished

Jun 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The subjects in the study were enrolled from different centers (public and private sectors) across different regions in the country; East, Center and West of Algeria.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient, male or female, aged ≥ 19 years. * Patient with a diagnosis of atrial fibrillation who requires treatment with Trombix® or switch of Anti-Vitamin K treatment toTrombix® (patient not balanced with current treatment or wishing to change treatment with better manageability). * Patient being able to provide free and informed written consent before the study. Exclusion Criteria: * Hypersensitivity to the active ingredient or to one of the excipients indicated in the Summary of Product Characteristics of Trombix® * Clinically significant progressive bleeding. * Injury or illness, if considered to be at significant risk of major bleeding. This may include: current or recent gastrointestinal ulceration, presence of malignant tumors with a high risk of bleeding, recent brain, spinal or ophthalmic surgery, recent intracranial hemorrhage, known or suspected esophageal varices, arteriovenous malformations, vascular aneurysms or major intra-spinal or intracerebral vascular anomalies. * Concomitant treatment with any other anticoagulant, for example, unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, dabigatran exilate, apixaban, etc.) except in specific circumstances of switching from anticoagulant treatment or in the case of administration of UFH at doses necessary to maintain the permeability of a central venous or arterial catheter. * Liver injury associated with coagulopathy and clinically significant bleeding risk, including cirrhotic patients with Child Pugh score class B or C. * Pregnancy and breast feeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation

Contacts and locations

Locations

  • AOUICHE private healthcare

    Constantine, Algeria

  • Ali Lahmar private healthcare

    Oran, Algeria

  • BEDAI private healthcare

    Annaba, Algeria

  • Berboucha

    Annaba, Algeria

  • Boudjelal private healthcare

    Batna City, Algeria

  • Boumaaza Private healthcare

    Algiers, Algeria

  • CHU Mustapha

    Algiers, Algeria

  • CHU Oran

    Oran, Algeria

  • EID private healthcare

    Oran, Algeria

  • EPH Tipaza

    Tipasa, Algeria

  • Fernane private healthcare

    Tizi Ouzou, Algeria

  • HAMDI private healthcare

    Constantine, Algeria

  • KHAITER Private healthcare

    Blida, Algeria

  • Mouffok private healthcare

    M'Sila, Algeria

  • NASSOUR private healthcare

    Tlemcen, Algeria

  • OKBI Private healthcare

    Biskra, Algeria

  • Sebbagh Private Healthcare

    Sidi Bel Abbes, Algeria

More trials for these conditions

Other studies related to the condition(s) this trial covers.